Ann: DEP irinotecan clinical data presented at AACR meeting, page-3

That's it @chrisnj ... perhaps JF & Co. should focus on all the overdue expected announcements touted to the market throughout 2023 instead of trying to distract everyone with DEP® irinotecan - 3 announcements about DEP® irinotecan in just over a month but nothing on the long awaited DEP® Docetaxel or DEP® Cabazitaxel phase 2 trials .... wonder no more why multiple Substantial Holders are bailing at huge losses


.... oh and look as I type another DEP® announcement that has nothing to do with the long awaited DEP® Docetaxel or DEP® Cabazitaxel phase 2 trials ...